Related references
Note: Only part of the references are listed.IL10 trains macrophage profibrotic function after lung injury
Aritra Bhattacharyya et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2022)
Idiopathic pulmonary fibrosis: Current and future treatment
Daniel S. Glass et al.
CLINICAL RESPIRATORY JOURNAL (2022)
Tacrolimus Treatment for Post-COVID-19 Interstitial Lung Disease
Migiwa Ohgushi et al.
INTERNAL MEDICINE (2022)
MBD2 serves as a viable target against pulmonary fibrosis by inhibiting macrophage M2 program
Yi Wang et al.
SCIENCE ADVANCES (2021)
Identification of ANXA2 (annexin A2) as a specific bleomycin target to induce pulmonary fibrosis by impeding TFEB-mediated autophagic flux
Kui Wang et al.
AUTOPHAGY (2018)
The JAK2 pathway is activated in idiopathic pulmonary fibrosis
Javier Milara et al.
RESPIRATORY RESEARCH (2018)
Macrophages: friend or foe in idiopathic pulmonary fibrosis?
Lei Zhang et al.
RESPIRATORY RESEARCH (2018)
Role of C/EBP homologous protein and endoplasmic reticulum stress in asthma exacerbation by regulating the IL-4/signal transducer and activator of transcription 6/transcription factor EC/IL-4 receptor α positive feedback loop in M2 macrophages
Yi Wang et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
Idiopathic pulmonary fibrosis
Luca Richeldi et al.
LANCET (2017)
Stretch-induced Activation of Transforming Growth Factor-β1 in Pulmonary Fibrosis
Aaron R. Froese et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2016)
Treatment of bleomycin-induced pulmonary fibrosis by inhaled tacrolimus-loaded chitosan-coated poly(lactic-co-glycolic acid) nanoparticles
Changkyu Lee et al.
BIOMEDICINE & PHARMACOTHERAPY (2016)
Chop Deficiency Protects Mice Against Bleomycin-induced Pulmonary Fibrosis by Attenuating M2 Macrophage Production
Yingying Yao et al.
MOLECULAR THERAPY (2016)
Therapeutic advantage of inhaled tacrolimus-bound albumin nanoparticles in a bleomycin-induced pulmonary fibrosis mouse model
Jisoo Seo et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2016)
FK506-Binding Protein 10, a Potential Novel Drug Target for Idiopathic Pulmonary Fibrosis
Claudia A. Staab-Weijnitz et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2015)
Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review
John Hutchinson et al.
EUROPEAN RESPIRATORY JOURNAL (2015)
miR-142-5p and miR-130a-3p are regulated by IL-4 and IL-13 and control profibrogenic macrophage program
Shicheng Su et al.
NATURE COMMUNICATIONS (2015)
Tacrolimus abrogates TGF-β1-induced type I collagen production in normal human fibroblasts through suppressing p38MAPK signalling pathway: implications on treatment of chronic atopic dermatitis lesions
C. -C. E. Lan et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2014)
Successful Treatment with Tacrolimus in a Case of Lung-dominant Connective Tissue Disease
Masaki Okamoto et al.
INTERNAL MEDICINE (2013)
An Official ATS/ERSARS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management
Ganesh Raghu et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)
Tacrolimus and Steroid Treatment for Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Nobuyuki Horita et al.
INTERNAL MEDICINE (2011)
Use of tacrolimus, a potent antifibrotic agent, in bleomycin-induced lung fibrosis
J Nagano et al.
EUROPEAN RESPIRATORY JOURNAL (2006)
Tacrolimus (FK506) has protective actions against murine bleomycin-induced acute lung injuries
T Koshika et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2005)
Share Paper
